DNA 拓扑异构酶（DNA topoisomerase，Topo）是细胞凋亡过程中关键的核内酶，Topo 抑制剂通过作用于 Topo 抑制肿瘤的活性。然而在临床中，单独使用一种 Topo 抑制剂常常引发多药耐药性。研究证明，两种 Topo 抑制剂联合用药存在协同作用可以逆转这种多药耐药性，但这种联合与药物组配、肿瘤特点和给药顺序密切相关，本文就这种联合用药在逆转肿瘤多药耐药中的研究进展做一综述。%DNA topoisomerase(Topo)is a kind of nuclear enzyme,which plays an important role in the process of cell apoptosis. TopoⅠnhibitors act on Topo to inhibit tumor activity. In clinical,however,using TopoⅠnhibitor alone often leads to multidrug resistance. Studies have shown that the synergistic effect which result from combination regi-men of two TopoⅠnhibitors can reverse multidrug resistance,but this kind of combination is related closely to drug proportion,tumor features and delivery schedule. This paper reviews research progress on the drug combination in re-versing multidrug resistance of tumor.
展开▼
